Should You Buy Aurora Cannabis Inc (ACB) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
4.420
1 Day change
2.31%
52 Week Range
6.910
Analysis Updated At
2026/01/22
Aurora Cannabis Inc (ACB) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock shows weak technical indicators, mixed sentiment from options data, and financials that, while improving, still reflect significant challenges. Positive news catalysts exist, but they are not strong enough to outweigh the risks.
Technical Analysis
The technical indicators are bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 46.081, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate a pivot at 4.217, with resistance at 4.352 and support at 4.081. The stock has a 40% chance of a minor gain (1.76%) in the next day but a higher likelihood of losses (-3.94% in the next week and -15.67% in the next month).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The options data suggests a slightly bullish sentiment, with the put-call ratios below 1. However, the implied volatility (IV) is high at 79.2, and the IV percentile is 42.4, indicating moderate demand for options. The IV rank is low at 7.18, suggesting the stock is not at a volatility extreme.
Moving Average Consensus
Sell
8
Buy
5
Positive Catalysts
2026/01/22 06:06:23
Aurora Cannabis has secured EU plant variety rights for its strains, which enhances its market potential in Europe.
Optimism around federal cannabis reform in the U.S., including President Trump's executive order to reschedule cannabis, could reduce tax burdens for cannabis operators.
Revenue increased by 11.40% YoY in Q2 2026.
Neutral/Negative Catalysts
2026/01/22 06:06:23
Gross margin dropped significantly to -8.86%, down -968.63% YoY, reflecting operational inefficiencies.
Net income remains negative at -$51.47M, despite improvements.
The stock trend analysis indicates a higher likelihood of losses in the short to medium term.
No recent significant hedge fund, insider, or congress trading activity to support confidence in the stock.
Financial Performance
In Q2 2026, Aurora Cannabis reported revenue growth of 11.40% YoY to $90.37M. Net income improved significantly by 319.14% YoY but remains negative at -$51.47M. EPS also improved by 313.64% YoY to -0.91. However, the gross margin dropped drastically to -8.86%, down -968.63% YoY, indicating operational challenges.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No recent analyst rating or price target changes were provided. Wall Street sentiment appears neutral, with no significant hedge fund or insider activity.
Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
